Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors

While the role of prostaglandin E2 (PGE2) in promoting malignant progression is well established, how to optimally block the activity of PGE2 signaling remains to be demonstrated. Clinical trials with prostaglandin pathway targeted agents have shown activity but without sufficient significance or do...

Descripción completa

Detalles Bibliográficos
Autores principales: Francica, Brian J., Holtz, Anja, Lopez, Justine, Freund, David, Chen, Austin, Wang, Dingzhi, Powell, David, Kipper, Franciele, Panigrahy, Dipak, Dubois, Raymond N., Whiting, Chan C., Prasit, Peppi, Dubensky, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408683/
https://www.ncbi.nlm.nih.gov/pubmed/37559947
http://dx.doi.org/10.1158/2767-9764.CRC-23-0249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408683/
https://www.ncbi.nlm.nih.gov/pubmed/37559947
http://dx.doi.org/10.1158/2767-9764.CRC-23-0249

Ejemplares similares